Futura Medical Share Discussion Threads

[broomrigg] 16/4/2024 14:20

Posted on LSE, Portugal website up and running.....

[mdi] 16/4/2024 14:19

More like Futura does not make progress. Except on removing the reminders of all the other products that produced nothing like was claimed to be expected back when they launched.



‘PET500 is expected to produce royalties of between £8m and £10m a year’

[mdi] 16/4/2024 11:10

All references to PET500/Epic spray have now vanished from the Futura website?



January 2014

Futura Medical Epic launch by Ansell in US market

˜The financial terms of the Ansell worldwide licensing agreement are not disclosed but Futura Medical estimates that a 5% share of the global OTC performance-enhancement market would result in royalties of £8-10m per year’

[mdi] 16/4/2024 10:34

More information has been again taken down from the Futura website. As happened before and was previously written about ‘The vanishing FAQ’

The Erection of a Placebo
When yesterday's placebo is tomorrow's treatment

[petroc] 16/4/2024 09:56

I think he finishes his security shift at 8 in the morning, so he probably has. He must have forgotten to take his crayons last night because he didn't share his 'special' knowledge about Erexon/Eroxon, for a change!

[broomrigg] 16/4/2024 07:16

When do you reckon Glavey?

[glavey] 16/4/2024 04:35

Notable spend on plant & equipment last financial year - wonder what they bought.
Anyone have any ideas as to the timing of the next cash raise?

[mdi] 15/4/2024 23:37

Also according to Ceuta if ‘Online provided the majority of sales’ for Eroxon. Is that how Futura were able come up with the market share they touted in the RNS that Eroxon supposedly captured in the early days of launching in UK and Belgium of ‘c. 20% market share of approved ED treatments’. So Eroxon actually just captured 20% of a smalll online market of approved ED treatments ie mainly online sales of other medical devices which are also all ‘approved ED treatments. But which mostly excludes the online sale of drugs like Viagra, Cialis etc. As online sales are mostly an ’option not open to “pharmacy” (P) classified medicines like sildenafil and tadalafil, which can only be dispensed after consultation with a pharmacy professional’

[mdi] 15/4/2024 21:38

And yet another contradiction to what Futura told shareholders. The UK distributor Ceuta Healthcare, marketing director Jon Connolly said ‘Online provided the majority of sales’ ‘While physical sales were “kind of slow”. So again they could track the majority of online sales and give a repurchase rate.But maybe they didn’t want more detailed figures. As it already appears to be obvious from the declining revenues what is happening. Eroxon revenue was £1.7m in April/May and only £1.4m in the following 6 months

[petroc] 15/4/2024 20:32

MDI, it's impossible to underestimate you. There was a little too much chlorine in your gene pool. You don’t need to fear success, you have nothing to worry about.

[mdi] 15/4/2024 19:48

Here is another contradiction to what was claimed in the Futura presentation. About them not being unable to provide any details to shareholders on repeat purchasers?

‘If a someone wants to buy Eroxon on Amazon, their credit card details and delivery addresses are already there’

[mdi] 15/4/2024 16:42

Sounds like during the launch ‘hype cycle’ they got journalists to print headlines that ‘wouldn’t be allowed’ in advertising?



‘Thanks to help from marketing firm Jungle Cat Solutions, Ceuta was able to use PR effectively’

‘The PR was phenomenal,” Connolly commented. “Those headlines just had potency that you would never, ever be able to get in advertising because they just wouldn't be allowed’

Wellness Investors:

Beware The Placebo Trap

Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones

[petroc] 15/4/2024 16:19

I would explain it to you, MDI/LBO etc, but I don't have the time or the crayons.

[mdi] 15/4/2024 15:56

Don’t forget Futura apparently won an award for spending the best big budget on marketing Eroxon. And since Eroxon only launched in April 2023 they managed to spend the over £0.5 million required in marketing in an even shorter period. Just between April 2023 - August 2023. Again more evidence of the ‘hype cycle’. Also I dont understand why Futura win an award for what Cooper are supposed to be spending on marketing?



BEST BIG BUDGET OTC MARKETING CAMPAIGN

This Award is designed for big-budget OTC brands which have been supported by a total marketing spend – both above-the-line and below-the – line – exceeding £0.5 million between August 2022 – August 2023

WINNER

Eroxon, Futura Medical

[mdi] 15/4/2024 12:43

Sales of Eroxon apparently £1.7m in April/May, followed by £1.4m in the following 6 months? That revenue deceleration is telling there was a large ‘hype cycle’ that may have misled some men in new launch markets to buy and believe the ‘hype’ around a ‘clinically proven’ placebo hydroalcoholic gel. Especially a gel that was only tested on men who had to already report being able to respond to manual stimulation. But eventually they will run out of new markets to launch to prop up the declining revenue in markets they have launched and the hype is giving way to complaints about being misled?



Wellness Investors: Beware The Placebo Trap

Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones.

Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’t due to the hype cycle, but rather the placebo cycle.